Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature

被引:1
|
作者
Karvigh, Sanaz Ahmadi [1 ]
Salehizadeh, Saeideh [1 ]
Vahabizad, Fahimeh [1 ]
机构
[1] Univ Tehran Med Sci, Sina Hosp, Dept Neurol, Tehran, Iran
关键词
LGI1; Faciobrachial dystonic seizure (FBDS); Basal ganglia; Immunotherapy; Rituximab; Autoimmune encephalitis; FACIOBRACHIAL DYSTONIC SEIZURES; LGI1; IMMUNOTHERAPY; ANTIBODIES; RITUXIMAB; THERAPY; CASPR2;
D O I
10.1186/s13256-022-03650-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Anti-leucine-rich glioma-inactivated 1 encephalitis is a newly emerged entity characterized by frequent faciobrachial dystonic seizures and a wide spectrum of subacute clinical symptoms such as other seizure types, mood and behavioral changes, and memory loss. We should be aware of differentiating this diagnosis from psychogenic nonepileptic seizures. Mesial temporal, limbic structures, and basal ganglia are the most commonly involved regions. Case presentation Here we review the available data, and report on two young Iranian (White) females, 24 and 18 years old, who represent distinct aspects of the disease. The clinical presentation and degree of tissue involvement varies to some extent in the two reported cases. Case 1 had prominent neuropsychiatric symptoms and suffered from frequent faciobrachial dystonic seizures with more significant basal ganglia involvement, whereas case 2 suffered from severe memory decline and dialeptic seizures along with mesial temporal involvement. Symptoms were refractory to usual treatment and prompt immunotherapy was needed. Conclusions This disease has a rather favorable outcome provided that treatment is initiated early. However, resistance to first-line treatment, relapses, and long-term complications highlight the need to establish reliable biomarkers to distinguish different subtypes of this disorder to predict the clinical outcome and prognosis, and to refine management.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Rethinking Outcomes in Leucine-Rich, Glioma-Inactivated 1 Protein Encephalitis "Good" Isn't Good Enough
    Day, Gregory S.
    JAMA NEUROLOGY, 2017, 74 (01) : 19 - 21
  • [42] A Case of Anti-Leucine-Rich Glioma-Inactivated Protein 1 (Anti-LGI1) Encephalitis With an Unusual Frontomesial Motor Cortex T2 MRI Hyperintensity
    Papiri, Giulio
    Puca, Emanuele
    Marcucci, Matteo
    Paci, Cristina
    Cagnetti, Claudia
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (10)
  • [43] Rituximab as a Treatment for Limbic Encephalitis Associated with Leucine-Rich Glioma Inactivated 1: A Case Report and Literature Review
    Lima, Behnam Safarpour
    Ramezani, Mahtab
    Kareviialavueh, Ehsan
    Paybast, Sepideh
    Beladimoghadam, Nahid
    Nazer, Nikoo Hossein Khan
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2019, 7 (01): : 70 - 73
  • [44] Leucine-rich glioma-inactivated 1 antibody encephalitis as a rare cause of delirium
    Ching, Emily
    Murdoch, Hannah
    Mohammed, Hamzah
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2022, 22 (12) : 1047 - 1048
  • [45] MR Imaging Findings in Anti-Leucine-Rich Glioma Inactivated Protein 1 Encephalitis: A Systematic Review and Meta-analysis
    Almeida, Francisco C.
    Pereira, Ana I.
    Mendes-Pinto, Catarina
    Lopes, Joana
    Moura, Joao
    Sousa, Jose Maria
    Videira, Goncalo
    Samoes, Raquel
    Oliveira, Tiago Gil
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2024, 45 (07) : 977 - 986
  • [46] CHI3L1 in the CSF is a potential biomarker for anti-leucine-rich glioma inactivated 1 encephalitis
    Li, Jinyi
    Li, Hongyan
    Wang, Yunhuan
    Zhao, Xiuhe
    Wang, Shengjun
    Li, Ling
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [47] Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome: Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2
    Murayama, Aki
    Sugaya, Keizo
    Hara, Makoto
    Kawazoe, Tomoya
    Tobisawa, Shinsuke
    Nakajima, Hideto
    Takahashi, Kazushi
    INTERNAL MEDICINE, 2023, 62 (11) : 1659 - 1663
  • [48] Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies)
    Bastiaansen, Anna E. M.
    van Sonderen, Agnes
    Titulaer, Maarten J.
    CURRENT OPINION IN NEUROLOGY, 2017, 30 (03) : 302 - 309
  • [49] Electroencephalographic findings in antileucine-rich glioma-inactivated 1 (LGI1) autoimmune encephalitis: A systematic review
    Roberto, Katrina T.
    Espiritu, Adrian, I
    Fernandez, Marc Laurence L.
    Gutierrez, Josephine C.
    EPILEPSY & BEHAVIOR, 2020, 112
  • [50] Anti-leucine-rich-glioma-inactivated 1 Limbic Encephalitis: An Underrecognised Disease
    Nabi, Danish
    Ayaz-Ul-Haq, Mian
    Alam, Mehtab
    Ali, Saqib
    Ismail, Shoaib
    Lqbal, Amjad
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2021, 31 (09): : 1105 - 1107